Erasca, Inc. (ERAS)
NASDAQ: ERAS · Real-Time Price · USD
16.19
-0.07 (-0.43%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Erasca Employees
Erasca had 103 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
103
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,788,573
Market Cap
5.66B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 103 | 0 | - |
| Dec 31, 2024 | 103 | -23 | -18.25% |
| Dec 31, 2023 | 126 | -3 | -2.33% |
| Dec 31, 2022 | 129 | 6 | 4.88% |
| Dec 31, 2021 | 123 | 21 | 20.59% |
| Jun 30, 2021 | 102 | - | - |
| Mar 31, 2021 | 102 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 433 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Cogent Biosciences | 258 |
| Parabilis Medicines | 145 |
| Definium Therapeutics | 106 |
ERAS News
- 5 days ago - Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - GlobeNewsWire
- 11 days ago - Erasca price target raised to $33 from $25 at JPMorgan - TheFly
- 14 days ago - Erasca granted Fast Track Designation for ERAS-0015 - TheFly
- 14 days ago - Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma - GlobeNewsWire
- 21 days ago - Erasca price target raised to $22 from $18 at H.C. Wainwright - TheFly
- 21 days ago - Erasca price target raised to $21 from $20 at Guggenheim - TheFly
- 22 days ago - Erasca price target raised to $20 from $18 at BofA - TheFly
- 26 days ago - Erasca reports Q2 EPS (14c), consensus (11c) - TheFly